A detailed history of Pro Share Advisors LLC transactions in Relay Therapeutics, Inc. stock. As of the latest transaction made, Pro Share Advisors LLC holds 26,214 shares of RLAY stock, worth $166,721. This represents 0.0% of its overall portfolio holdings.

Number of Shares
26,214
Previous 22,820 14.87%
Holding current value
$166,721
Previous $251,000 13.55%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 08, 2024

BUY
$7.5 - $12.07 $25,455 - $40,965
3,394 Added 14.87%
26,214 $217,000
Q4 2023

Feb 14, 2024

BUY
$6.01 - $11.48 $18,673 - $35,668
3,107 Added 15.76%
22,820 $251,000
Q3 2023

Nov 13, 2023

BUY
$8.24 - $12.97 $840 - $1,322
102 Added 0.52%
19,713 $165,000
Q2 2023

Aug 10, 2023

BUY
$9.99 - $18.27 $11,768 - $21,522
1,178 Added 6.39%
19,611 $246,000
Q1 2023

May 11, 2023

SELL
$15.0 - $22.76 $37,755 - $57,286
-2,517 Reduced 12.01%
18,433 $303,000
Q4 2022

Feb 02, 2023

BUY
$14.16 - $24.02 $47,506 - $80,587
3,355 Added 19.07%
20,950 $312,000
Q3 2022

Nov 04, 2022

BUY
$18.07 - $31.37 $9,721 - $16,877
538 Added 3.15%
17,595 $394,000
Q2 2022

Aug 01, 2022

SELL
$13.31 - $34.88 $96,763 - $253,577
-7,270 Reduced 29.88%
17,057 $286,000
Q1 2022

May 10, 2022

SELL
$20.26 - $32.36 $125,064 - $199,758
-6,173 Reduced 20.24%
24,327 $728,000
Q4 2021

Feb 08, 2022

BUY
$26.0 - $37.03 $78,130 - $111,275
3,005 Added 10.93%
30,500 $936,000
Q3 2021

Nov 12, 2021

SELL
$29.75 - $37.99 $127,657 - $163,015
-4,291 Reduced 13.5%
27,495 $867,000
Q2 2021

Aug 13, 2021

BUY
$27.5 - $38.19 $194,700 - $270,385
7,080 Added 28.66%
31,786 $1.16 Million
Q1 2021

May 14, 2021

BUY
$32.52 - $61.53 $120,063 - $227,168
3,692 Added 17.57%
24,706 $854,000
Q4 2020

Feb 09, 2021

BUY
$35.51 - $54.03 $746,207 - $1.14 Million
21,014 New
21,014 $873,000

Others Institutions Holding RLAY

About Relay Therapeutics, Inc.


  • Ticker RLAY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 120,219,000
  • Market Cap $765M
  • Description
  • Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...
More about RLAY
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.